Prolight Diagnostics publishes investor letter for November 2025

The investor letter notes, among other things that Prolight takes clear steps toward commercialization of the Psyros™ POC system.

The investor letter is available via the attached file or on the company’s website: https://prolightdx.com/en/mediaeng/investor-letters/

For further information, please contact:
Ulf Bladin, CEO
E-mail: info@prolightdx.com
Phone: +46 73 582 39 87
Company website: www.prolightdx.com

About Us
Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.
 
The company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments
Prolight Diagnostics – Investerarbrev November 2025 ENG
Prolight Diagnostics publishes investor letter for November 2025

Prolight Diagnostics - Investerarbrev November 2025 ENG
Prolight Diagnostics publishes investor letter for November 2025
Back

Subscribe

Privacy policy